ANASTRO1 — IN DEPTH.
What Anastrozole is
Anastrozole, sold as Arimidex by AstraZeneca and several generic manufacturers, is a third-generation non-steroidal aromatase inhibitor (AI). It selectively binds the aromatase enzyme and prevents the conversion of androgens to estrogens. It is a first-line endocrine treatment for hormone-receptor-positive breast cancer in post-menopausal women, and it is the most commonly used AI in anabolic-steroid cycle support.
Pharmacology and kinetics
Plasma half-life is approximately 50 hours, giving anastrozole a long, stable suppression of estradiol production from a single dose. Steady-state serum levels are reached after about a week of regular administration. Anastrozole is reversible — once dosing stops, aromatase activity recovers within days — which makes it easy to titrate against bloodwork.
Where it fits in a cycle
Anastrozole is an on-cycle estrogen control compound, used to keep estradiol within physiological range while running aromatising anabolics such as testosterone, methandienone or oxymetholone. Typical doses range from 1 mg twice per week to 1 mg every other day, adjusted against E2 bloodwork — over-suppression of estrogen is its own problem and produces joint pain, lipid disturbance and libido loss.
What to expect
Controlled estradiol levels, reduced water retention, lower risk of gynecomastia, and predictable on-cycle bloodwork when dosed correctly. It is not a PCT compound — SERMs (clomiphene, tamoxifen) are used for HPTA recovery instead.
Blackbird Pharma's preparation
Anastro 1 is supplied as 50 oral capsules of micronised anastrozole in microcrystalline cellulose with a gelatin shell. Each active batch is supported by an independent EU laboratory certificate confirming identity and per-capsule content.
